A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome

The purpose of this study is to determine whether LCQ908 is effective and safe in lowering triglycerides in subjects with Familial Chylomicronemia Syndrome (FCS) (Hyperlipoproteinemia [HLP] type I). Data from this study will be used to support a registration submission of LCQ908 20 mg and 40 mg as treatment of chylomicronemia in subjects with FCS (HLP Type 1).

Study Overview

• Status: Completed
• Conditions: Familial Chylomicronemia Syndrome (FCS)
• Intervention / Treatment: Drug: LCQ908; Drug: Placebo

• Study Type: Interventional
• Enrollment (Actual): 45
• Phase: Phase 3

Contacts and Locations

Study Locations

• Canada
  • Ouest-Montreal, Canada, H2W1R7
    • Novartis Investigative Site
  • Quebec
    • Chicoutimi, Quebec, Canada, G7H 7P2
      • Novartis Investigative Site
    • Ste-Foy, Quebec, Canada, G1V4M6
      • Novartis Investigative Site
• France
  • Bron, France, 69677
    • Novartis Investigative Site
  • Nantes, France, 44093
    • Novartis Investigative Site
  • Paris Cedex 13, France, 75651
    • Novartis Investigative Site
• Germany
  • Hamburg, Germany, 20246
    • Novartis Investigative Site
  • Köln, Germany, 50937
    • Novartis Investigative Site
• Netherlands
  • Meibergdreef 9, Netherlands, 1105 AZ
    • Novartis Investigative Site
• South Africa
  • Cape Town, South Africa, 7925
    • Novartis Investigative Site
• Spain
  • Andalucia
    • Malaga, Andalucia, Spain, 29010
      • Novartis Investigative Site
    • Sevilla, Andalucia, Spain, 41013
      • Novartis Investigative Site
• United Kingdom
  • Manchester, United Kingdom, M13 9NT
    • Novartis Investigative Site
• United States
  • Washington
    • Seatlle, Washington, United States, 98104
      • Novartis Investigative Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Key Inclusion Criteria:

1. Written informed consent given before any assessment was performed for Period I.
2. Male and female patients ages at least 18 years of age.
3. Fasting triglyceride ≥ 8.4 mmol/L (750 mg/dL) at Screening.

4. An established diagnosis of FCS (HLP Type I) confirmed through ultracentrifugation or by documented medical history of a fasting triglyceride ≥ 8.4 mmol/L (750 mg/dL) and by documentation of any of the following at Screening or during the Screening Period:

   • Confirmed homozygote or compound heterozygote for known loss-of-function mutations in Type I-causing genes (such as LPL, apo C II, GPIHBP1, or LMF1)
   • Post heparin plasma LPL activity of ≤ 20% of normal
   • Confirmed presence of LPL inactivating antibodies
5. History of pancreatitis.

Key Exclusion Criteria:

1. Current pancreatitis, pancreatitis was required to be inactive for at least 1 week prior to the screening Visit.
2. Treatment with fish oil preparations within 4 weeks prior to randomization.
3. Treatment with bile acid binding resins (i.e., colesevelam, etc.) within 4 weeks prior to randomization.
4. Treatment with fibrates within 4 weeks prior to randomization.
5. Glybera [alipogene tiparvovec (AAV1-LPLS447X)] gene therapy exposure within the two years prior to screening.
6. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
7. Any surgical or medical conditions, acute or unstable chronic disease which may, based on the investigator's opinion, jeopardize the patient in case of participation in the study or might significantly alter the absorption, distribution, metabolism or excretion of the study drug.
8. History of drug or alcohol abuse within the 12 months prior to randomization or evidence of such abuse at screening.
9. Evidence of liver disease or liver injury as indicated by abnormal liver function tests such as aspartate aminotransferase (AST) and alanine aminotransferase (ALT), or serum bilirubin.
10. Estimated glomerular filtration rate (eGFR) <30mL/min/1.73m2 or history of chronic renal disease.
11. Participation in any clinical investigation within four (4) weeks prior to initial dosing or longer if required by local regulations, or any other limitation of participation based on local regulations.
12. History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes.
13. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive HCG laboratory test.
14. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 100 days after discontinuation of investigational study drug.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: LCQ908 20 mg; In period II (0-12 weeks) double-blind treatment: one LCQ908 20 mg active tablet + one LCQ908 placebo matching to 40mg tablet, once daily. No dose titration allowed. In period III (12-52 weeks) double blind treatment: Without down titration, the period II dosing regimen will follow. Following decision to down titrate: one LCQ908 10 mg active tablet + one LCQ908 placebo matching to 40 mg tablet + one LCQ908 placebo matching to 10mg tablets, once daily. A low fat diet will be followed and recorded in patient diary.	Drug: LCQ908; LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg; Drug: Placebo; LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg; Other Names: LCQ908
Experimental: LCQ908 40 mg; In period II (0-12 weeks) double-blind treatment: one LCQ908 40 mg active tablet + one LCQ908 placebo matching to 20mg tablet, once daily. No dose titration allowed. In period III (12-52 weeks) double blind treatment: Without down titration, the period II dosing regimen will follow. Following decision to down titrate: one LCQ908 20 mg active tablet + one LCQ908 placebo matching to 40 mg tablet + one LCQ908 placebo matching to 10mg tablets, once daily. A low fat diet will be followed and recorded in patient diary.	Drug: LCQ908; LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg; Drug: Placebo; LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg; Other Names: LCQ908
Placebo Comparator: Placebo; In period II (0-12 weeks) double-blind treatment: one LCQ908 placebo matching to 40mg tablet + one LCQ908 placebo matching to 20mg tablet, once daily. In period III (12-52 weeks) double blind treatment: Without down titration, the period II dosing regimen will follow. Following decision to down titrate: one LCQ908 placebo matching to 40mg tablet + one LCQ908 placebo matching to 20mg tablet + one LCQ908 placebo matching to 10mg tablets, once daily. A low fat diet will be followed and recorded in patient diary.	Drug: Placebo; LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg; Other Names: LCQ908

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percent Change in Fasting Triglycerides From Baseline to 12 Weeks	Blood samples were collected for a fasting lipid panel, including triglycerides. If the 12-week value was missing, the measurement value at 12 weeks or the last available post-baseline measurement value during the double-blind treatment period was analyzed. Baseline is defined as the average of fasting triglyceride values taken at day -3 and day 1. Adjusted geometric means are calculated by back-transforming the adjusted means from the model and expressing as a percentage change from baseline.	Baseline to 12 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Patients Responding to Investigational Treatment by Achieving Fasting Triglycerides (TG) of at Least 40% From Baseline or Final Fasting TG < 8.4 mmol/L (750 mg/dL)	Percentage calculated as (m/n)*100 where m = number of patients who respond; n = the number of patients with non-missing fasting triglyceride.	Baseline, 12 weeks, 24 weeks, 52 weeks
Percentage of Patients Responding to Investigational Treatment by Achieving Final Fasting Triglycerides < 8.4 mmol/L (750 mg/dL)	Percentage calculated as (m/n)*100 where m = number of patients who respond; n = the number of patients with non-missing fasting triglyceride.	12 weeks, 24 weeks, 52 weeks
Percentage of Patients Responding to Investigational Treatment by Achieving Fasting Triglycerides (TG) of at Least 40% From Baseline	Percentage calculated as (m/n)*100 where m = number of patients who respond; n = the number of patients with non-missing fasting triglyceride.	Baseline, 12 weeks, 24 weeks, 52 weeks
Percentage of Patients Achieving Fasting Triglycerides (TG) Target Thresholds	Percentage of patients reaching target values of <1000 mg/dL or target values of < 2000 mg/dL for fasting triglycerides is reported. Pecentage calculated as (m/n)*100; where 'm' The number of patients who reach target values for fasting triglyceride, 'n' the number of patients with non-missing fasting triglyceride.	12 weeks, 24 weeks, 52 weeks
Percent Change From Baseline in Fasting Triglycerides		Baseline, 24 weeks, 52 weeks
Percent Change From Baseline for Postprandial Triglycerides Following the Standardized Meal Tolerance Test at Week 12	Post prandial peak triglycerides - maximum triglyceride value over 0-24 hours Post prandial triglycerides AUC0-24 - area under the time curve for triglycerides over 0-24 Adjusted geometric means are calculated by back-transforming the adjusted means from the model and expressed as a percentage change from baseline. hours	0-24 hours at Baseline, Week 12
Pharmacokinetics of LCQ908 - Trough Concentration (Cmin) and Observed Maximum Blood Concentration (Cmax)	Lowest observed blood concentration (Cmin) and observed maximum blood concentration (Cmax) following drug administration derived from non-compartmental analysis using scheduled sampling time for the whole dataset.	0, 1, 2, 3, 4, 6, and 24 hours at Week 12
Pharmacokinetics of LCQ908- Area Under the Plasma Concentration Time Curve AUC (0-24hour)	The area under the concentration-time curve from time zero to 24 hours after drug administration was calculated by using linear trapezoidal rule.	0, 1, 2, 3, 4, 6, and 24 hours at Week 12
Pharmacokinetics of LCQ908- Time to Reach Maximum Concentration Following Drug Administration Tmax (Hours)		0, 1, 2, 3, 4, 6, and 24 hours at Week 12
Pharmacokinetics of LCQ908- Average Observed Blood Concentration (Cavg)	Average observed blood concentration measured by (AUC0-24)/24.	0, 1, 2, 3, 4, 6, and 24 hours at Week 12
Number of Patients Reported With Any Adverse Event, Serious Adverse Event and Death		52 weeks

Collaborators and Investigators

• Sponsor: Novartis Pharmaceuticals

Study record dates

Study Major Dates

• Study Start: July 1, 2012
• Primary Completion (Actual): May 1, 2014
• Study Completion (Actual): May 1, 2014

Study Registration Dates

• First Submitted: December 21, 2011
• First Submitted That Met QC Criteria: January 20, 2012
• First Posted (Estimate): January 23, 2012

Study Record Updates

• Last Update Posted (Estimate): June 3, 2015
• Last Update Submitted That Met QC Criteria: May 15, 2015
• Last Verified: May 1, 2015

More Information

Terms related to this study

• Keywords: Fasting Triglycerides; Hyperlipoproteinemia (HLP Type I)
• Additional Relevant MeSH Terms: Pathologic Processes; Metabolic Diseases; Disease; Genetic Diseases, Inborn; Metabolism, Inborn Errors; Lipid Metabolism Disorders; Hyperlipidemias; Dyslipidemias; Lipid Metabolism, Inborn Errors; Hyperlipoproteinemias; Syndrome; Hyperlipoproteinemia Type I
• Other Study ID Numbers: CLCQ908B2302; 2011-005535-68 (EudraCT Number)